Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia

European Journal of Cancer

Volumn 46, Issue 10, 2010, Pages 1781-1789

  Boschelli, Frank ^a   Arndt, Kim ^a   Gambacorti Passerini, Carlo ^b  

^a WYETH RESEARCH   (United States)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

Bcr Abl; Bosutinib; Breast cancer; Chronic myelogenous leukaemia; Clinical trials; Imatinib resistance; SKI 606; Src; Tumour; Tyrosine kinase inhibitor

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; KX 01; KX 2391; MULTIDRUG RESISTANCE PROTEIN; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NILOTINIB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; UNCLASSIFIED DRUG; 3-QUINOLINECARBONITRILE N-OXIDE; AMINE OXIDE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NITRILE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINOLINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IC 50; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR UPREGULATION; SOLID TUMOR; SRC HOMOLOGY DOMAIN; TREATMENT DURATION; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL COMMUNICATION; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; CYCLIC N-OXIDES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; NEOPLASM TRANSPLANTATION; NITRILES; PROTEIN KINASE INHIBITORS; QUINOLINES; SRC-FAMILY KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 77953289990     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.032     Document Type: Article

References (67)

1. Kopetz S., Shah A.N., and Gallick G.E. Src continues aging: current and future clinical directions. Clin Cancer Res 13 24 (2007) 7232-7236
2. Hennequin L.F., Allen J., Breed J., et al. N-(5-Chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 49 22 (2006) 6465-6488
3. Lau G.M., Lau G.M., Yu G.L., et al. Expression of Src and FAK in hepatocellular carcinoma and the effect of src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci 54 7 (2009) 1465-1474
4. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumour activity in preclinical assays. J Med Chem 47 27 (2004) 6658-6661
5. Boschelli D.H., Ye F., Wang Y.D., et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 44 23 (2001) 3965-3977
6. Golas J.M., Arndt K., Etienne C., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63 2 (2003) 375-381
7. Brave M., Goodman V., Kaminskas E., et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14 2 (2008) 352-359
8. Puttini M., Coluccia A.M., Boschelli F., et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66 23 (2006) 11314-11322
9. Bantscheff M., Eberhard D., Abraham Y., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25 9 (2007) 1035-1044
10. Remsing Rix L.L., Rix U., Colinge J., et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23 3 (2009) 477-485
11. Dagher R., Cohen M., Williams G., et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumours. Clin Cancer Res 8 10 (2002) 3034-3038
12. Witte O. The role of Bcr-Abl in chronic myeloid leukemia and stem cell biology. Semin Hematol 38 3 Suppl. 8 (2001) 3-8
13. Mauro M.J., O'Dwyer M., Heinrich M.C., and Druker B.J. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20 1 (2002) 325-334
14. Bolen J.B., Veillette A., Schwartz A.M., DeSeau V., and Rosen N. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 84 8 (1987) 2251-2255
15. Cartwright C.A., Kamps M.P., Meisler A.I., Pipas J.M., and Eckhart W. Pp60c-src activation in human colon carcinoma. J Clin Invest 83 6 (1989) 2025-2033
16. c-src protein kinase activity in human tumour cell lines and tissues. J Biol Chem 261 29 (1986) 13754-13759
17. Jacobs C., and Rubsamen H. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res 43 4 (1983) 1696-1702
18. Talamonti M.S., Roh M.S., Curley S.A., and Gallick G.E. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91 1 (1993) 53-60
19. c-src activity in human colorectal metastases. J Surg Res 54 4 (1993) 293-298
20. Cartwright C.A., Meisler A.I., and Eckhart W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 87 2 (1990) 558-562
21. Aligayer H., Boyd D.D., Heiss M.M., et al. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94 2 (2002) 344-351
22. Irby R.B., and Yeatman T.J. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 62 9 (2002) 2669-2674
23. Jones R.J., Avizienyte E., Wyke A.W., et al. Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM12C human colorectal cancer cells. Br J Cancer 87 10 (2002) 1128-1135
24. Weis S., Cui J., Barnes L., and Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumour cell extravasation and metastasis. J Cell Biol 167 2 (2004) 223-229
25. Criscuoli M.L., Nguyen M., and Eliceiri B.P. Tumour metastasis but not tumour growth is dependent on Src-mediated vascular permeability. Blood 105 4 (2005) 1508-1514
26. Nam J.S., Ino Y., Sakamoto M., and Hirohashi S. Src family kinase Inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 8 7 (2002) 2430-2436
27. Myoui A., Nishimura R., Williams P.J., et al. C-SRC tyrosine kinase activity is associated with tumour colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 63 16 (2003) 5028-5033
28. Jallal H., Valentino M.L., Chen G., et al. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67 4 (2007) 1580-1588
29. Zheng R., Yano S., Matsumori Y., et al. SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells. Clin Exp Metastasis 22 3 (2005) 195-204
30. Du J., Bernasconi P., Clauser K.R., et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 27 1 (2009) 77-83
31. Desgrosellier J.S., Barnes L.A., Shields D.J., et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumour progression. Nat Med 15 10 (2009) 1163-1169
32. Riggins R.B., Thomas K.S., Ta H.Q., et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66 14 (2006) 7007-7015
33. Tatarov O., Mitchell T.J., Seywright M., et al. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 15 10 (2009) 3540-3549
34. Zhang X.H., Wang Q., Gerald W., et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16 1 (2009) 67-78
35. Boschelli D.H., Wang Y.D., Ye F., et al. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J Med Chem 44 5 (2001) 822-833
36. Wissner A., Overbeek E., Reich M.F., et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 46 1 (2003) 49-63
37. Rabindran S.K., Discafani C.M., Rosfjord E.C., et al. Antitumour activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64 11 (2004) 3958-3965
38. Wright D.D., Sefton B.M., and Kamps M.P. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol Cell Biol 14 4 (1994) 2429-2437
39. Graux C., Cools J., Melotte C., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 36 10 (2004) 1084-1089
40. Boschelli D.H., Boschelli F., Wu B., et al. SKI-606 and beyond. Hematol Rep 1 (2005) 28-31
41. Gambacorti-Passerini C, Brummendorf H, Kantarjian H, et al. Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib. In: ASCO Annual Meeting Proceedings; 2007. J Clin Oncol; 2007. p. 18S: 7006.
42. Mancini M., Brusa G., Zuffa E., et al. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. Leuk Res 31 7 (2007) 979-987
43. Konig H., Holyoake T.L., and Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111 4 (2008) 2329-2338
44. Konig H., Copland M., and Chu S. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 68 23 (2008) 9624-9633
45. Redaelli S., Piazza R., Rostagno R., et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27 3 (2009) 469-471
46. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukaemia in chronic phase: results from the International Randomized Phase III ENESTnd Trial. In: American Society for Hematology Annual Meeting, New Orleans; 2009.
47. Hegedus C., Ozvegy-Laczka C., Apati A., et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158 4 (2009) 1153-1164
48. Golas J.M., Lucas J., Etienne C., et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumour xenograft models. Cancer Res 65 12 (2005) 5358-5364
49. Dan I., Watanabe N.M., and Kusumi A. The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol 11 5 (2001) 220-230
50. Becker E., Huynh-Do U., Holland S., et al. Nck-interacting Ste20 kinase couples Eph receptors to c-Jun N-terminal kinase and integrin activation. Mol Cell Biol 20 5 (2000) 1537-1545
51. Shi C.S., Tuscano J.M., Witte O.N., and Kehrl J.H. GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway. Blood 93 4 (1999) 1338-1345
52. Shi C.S., Tuscano J., and Kehrl J.H. Adaptor proteins CRK and CRKL associate with the serine/threonine protein kinase GCKR promoting GCKR and SAPK activation. Blood 95 3 (2000) 776-782
53. Raitano A.B., Halpern J.R., Hambuch T.M., and Sawyers C.L. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 92 25 (1995) 11746-11750
54. Dickens M., Rogers J.S., Cavanagh J., et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277 5326 (1997) 693-696
55. Shi C.S., Huang N.N., Harrison K., Han S.B., and Kehrl J.H. The mitogen-activated protein kinase kinase kinase kinase GCKR positively regulates canonical and noncanonical Wnt signaling in B lymphocytes. Mol Cell Biol 26 17 (2006) 6511-6521
56. Wright J.H., Wang X., Manning G., et al. The STE20 kinase HGK is broadly expressed in human tumour cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 23 6 (2003) 2068-2082
57. Hu Y., Leo C., Yu S., et al. Identification and functional characterization of a novel human misshapen/Nck interacting kinase-related kinase, hMINK beta. J Biol Chem 279 52 (2004) 54387-54397
58. c-src-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 66 4 (2006) 2279-2286
59. Coluccia A.M., Vacca A., Dunach M., et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 26 5 (2007) 1456-1466
60. Zhang Y.X., Knyazev P.G., Cheburkin Y.V., et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 68 6 (2008) 1905-1915
61. Berclaz G., Altermatt H.J., Rohrbach V., et al. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol 12 6 (2001) 819-824
62. Campone M, Bondarenko I, Brincat S, et al. Preliminary results of a Phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer. In: 30th Annual San Antonio Breast Cancer symposium, 13-16 December 2007, San Antonio, TX; 2007.
63. 2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res 68 10 (2008) 3733-3742
64. Pasquale E.B. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133 1 (2008) 38-52
65. Noberini R., and Pasquale E.B. Proliferation and tumour suppression: not mutually exclusive for Eph receptors. Cancer Cell 16 6 (2009) 452-454
66. Genander M., Halford M.M., Xu N.J., et al. Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumour suppression. Cell 139 4 (2009) 679-692
67. Noren N.K., Foos G., Hauser C.A., and Pasquale E.B. The EphB4 receptor suppresses breast cancer cell tumourigenicity through an Abl-Crk pathway. Nat Cell Biol 8 8 (2006) 815-825